StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.43−0.01 (-0.69%)

Close on Nov 18, 2026Market cap $82.16MP/E –Yield –

Black Diamond Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Black Diamond Therapeutics

Black Diamond Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Black Diamond Therapeutics figures

See a number that looks wrong?